Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
epublish
Résumé
Despite the potential of targeted epigenetic therapies, most cancers do not respond to current epigenetic drugs. The Polycomb repressive complex EZH2 inhibitor tazemetostat was recently approved for the treatment of
Identifiants
pubmed: 38766189
doi: 10.1101/2024.05.03.592420
pmc: PMC11100591
pii:
doi:
Types de publication
Preprint
Langues
eng